BCMA-targeted therapies for multiple myeloma: latest updates from 2024 ASH annual meeting

Table 1 The characteristics of BCMA-targeted therapies regimen

Product	Target	Research design	Indication	Type	Clinical trial name	Clinical trial identifier	Refs.
Belantamab mafodotin	BCMA	BVd vs. DVd	R/R MM	ADC	DREAMM-7	NCT04246047	[2–3]
		BPd vs. PVd	R/R MM		DREAMM-8	NCT04484623	[4]
		Belantamab mafodotin + VRd	NDMM		DREAMM-9	NCT04091126	[5]
Teclistamab	BCMA x CD3	teclistamab + DP	R/R MM	BsAb	MajesTEC-2 TRIMM-2	NCT04722146 NCT04108195	[6]
		teclistamab + lenalidomide/teclistamab alone	NDMM		MajesTEC-4/EMN30	NCT04722146	[7]
		teclistamab + DRd/teclistamab + DVRd	NDMM		MajesTEC-5	NCT05695508	[8]
Cilta-cel	BCMA	Cilta-cel vs. SoC	R/R MM	CAR-T	CARTITUDE-4	NCT04181827	[9]
Anito-cel	BCMA	monotherapy	R/R MM	CAR-T	NA	NCT04155749	[10]
Anito-cel	BCMA	monotherapy	R/R MM	CAR-T	iMMagine-1	NCT05396885	[11]

R/R: relapsed/refractory; BCMA, b-cell maturation antigen; MM: multiple myeloma; ADC: antibody-drug conjugate; BsAbs: bispecific antibody, CAR-T: chimeric antigen receptor T cell; NDMM: newly diagnosed multiple myeloma; Cilta-cel: ciltacabtagene autoleucel; Anito-cel: anitocabtagene autoleucel; SoC: standard of care; BVd: belantamab mafodotin, bortezomib and dexamethasone; DVd: daratumumab, bortezomib and dexamethasone; BPd: belantamab mafodotin, pomalidomide and dexamethasone; PVd: pomalidomide, bortezomib and dexamethasone; VRd: bortezomib, lenalidomide and dexamethasone; DP: daratumumab and pomalidomide; DRd: daratumumab, lenalidomide and dexamethasone; DVRd: daratumumab, bortezomib, lenalidomide and dexamethasone; NR: not reached

ISSN: 1756-8722